A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-30

Study Completion Date

2027-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of CC312 in Autoimmune Disease Patients

NCT06888960

Systemic Lupus Erythematosus (SLE) Idiopathic Inflammatory Myopathy (IIM) Systemic Sclerosis (SSc) +3 more

RECRUITING EARLY_PHASE1

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

NCT07177911

SLE - Systemic Lupus Erythematosus

RECRUITING PHASE1

Study of CM355 in Patients With Systemic Lupus Erythematosus

NCT07104344

Systemic Lupus Erythematosus

NOT_YET_RECRUITING NA

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542

SLE (Systemic Lupus) Lupus Erythematosus, Systemic Lupus Nephritis +4 more

RECRUITING PHASE1

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

NCT06946485

Systemic Lupus Erythematosus (SLE)

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SLE - Systemic Lupus Erythematosus IIM- Idiopathic Inflammatory Myopathies SSc-Systemic Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CC312

Group Type EXPERIMENTAL

CC312

Intervention Type BIOLOGICAL

CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CC312

CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fully understand the trial's purpose, nature, methodology, and potential adverse reactions, voluntarily participate as a subject, and sign the informed consent form.
* Aged 18-65 years (inclusive, based on the date of signing the informed consent form), regardless of gender.
* For Systemic Lupus Erythematosus (SLE):

1. Diagnosed with SLE according to the 2019 EULAR/ACR classification criteria；
2. Meet at least one of the following: positive antinuclear antibody (ANA) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening；
3. Had an inadequate response or relapse after standard therapy, defined as any of the following (alone or combined): glucocorticoids, antimalarials (hydroxychloroquine), immunosuppressants (including mycophenolate mofetil, cyclophosphamide, leflunomide, methotrexate, tacrolimus, cyclosporine, azathioprine), or biologics (rituximab, belimumab, telitacicept). Each regimen must have been administered for ≥3 months, and the subject must have received ≥2 immunosuppressants and/or biologics；
4. At screening, meet SLEDAI-2000 ≥7 and have at least one BILAG A or two BILAG B organ domain scores；
5. Prior to the first dose, subjects must have received glucocorticoids and/or antimalarials and/or immunosuppressants for ≥12 weeks, with stable doses for ≥30 days；
6. If receiving oral glucocorticoids (e.g., prednisone), the dose must be ≤40 mg/day at screening and during the screening period；
7. If using glucocorticoids alone, the dose must be ≥7.5 mg/day prednisone (or equivalent).
* For Idiopathic Inflammatory Myopathy (IIM):

1. Diagnosed with possible or definite IIM per the 2017 EULAR/ACR classification criteria (≥5.5 points without biopsy; ≥6.7 points with biopsy) ；
2. Have at least one positive myositis-specific autoantibody (MSA) , myositis-associated autoantibody (MAA), or ANA at or prior to screening；
3. Had an inadequate response or relapse after conventional therapy, defined as glucocorticoids (prednisone \>1 mg/kg/day or equivalent) and ≥1 immunomodulatory drug (immunosuppressants: azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine; biologics: rituximab, belimumab; small molecules: tofacitinib), each for ≥3 months, with ≥2 immunosuppressants and/or biologics used；
4. Have active IIM at screening, defined as meeting ≥3 of MMT-8 total score ≤141/150 with ≥20% strength loss in affected muscles; Physician global activity ≥2; Patient global activity ≥2; MDAAT ≥2; ≥2 muscle enzymes elevated, with one ≥1.5× ULN; HAQ ≥0.25；
5. Prior to the first dose, subjects must have received glucocorticoids and/or immunosuppressants for ≥12 weeks, with stable glucocorticoid doses for ≥30 days and immunosuppressant doses for ≥60 days. Glucocorticoid dose must be ≤60 mg/day prednisone during screening；
6. If using glucocorticoids alone, the dose must be ≥7.5 mg/day prednisone.
* For Systemic Sclerosis (SSc):

1. Diagnosed with diffuse cutaneous SSc per the 2013 EULAR/ACR criteria ；
2. Have positive ANA and/or SSc-related antibodies (e.g., Scl70, Th/To, RP11/12, U3RNP)；
3. Disease duration ≤5 years (from initial diagnosis)；
4. Had an inadequate response or relapse after conventional therapy (glucocorticoids + ≥1 immunomodulator: cyclophosphamide, mycophenolate mofetil, methotrexate, leflunomide, azathioprine, tacrolimus, cyclosporine, and/or biologics), each for \>6 months；
5. mRSS ≥15 and ≤30 at screening with progression within 6 months；
6. Prior to the first dose, subjects must have received glucocorticoids and/or immunosuppressants for ≥12 weeks, with stable glucocorticoid doses for ≥30 days and immunosuppressant doses for ≥60 days. Glucocorticoid dose must be ≤10 mg/day during screening.
* Females of childbearing potential must use highly effective contraception from screening until 6 months after the last dose, refrain from oocyte donation, and ensure male partners use effective contraception.
* Males of childbearing potential must use effective contraception from screening until 6 months after the last dose, with no plans for fertility or sperm donation, and ensure female partners use effective contraception.

Exclusion Criteria

* Severe lupus nephritis within 8 weeks prior to screening (defined as urinary protein \>6 g/24 h, serum creatinine \>2.5 mg/dL or 221 μmol/L), requirement of prohibited medications for active nephritis per protocol, need for hemodialysis, or receipt of prednisone ≥100 mg/day (or equivalent glucocorticoids) for ≥14 days.
* Central nervous system disorders (including but not limited to epilepsy, psychosis, interstitial encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis) within 8 weeks prior to screening.
* Other types of idiopathic inflammatory myopathies: inclusion body myositis, amyotrophic diabetes, or juvenile myositis; patients with severe muscle damage or permanent weakness/cardiac involvement due to non-IIM causes (e.g., stroke).
* SSc-related pulmonary hypertension requiring treatment; rapidly progressive SSc-related lower gastrointestinal (small/large intestine) involvement requiring parenteral nutrition; active gastric antral vascular ectasia; history of SSc-related renal crisis.
* History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.
* Other concurrent autoimmune diseases requiring systemic therapy.
* IgA deficiency (serum IgA level \<10 mg/dL).
* Abnormal laboratory findings at screening: Liver function: AST/ALT \>2× upper limit of normal (ULN) (except for IIM patients with elevated muscle enzymes); Hematology: hemoglobin \<85 g/L, white blood cell count \<2.5×10⁹/L, platelet count \<50×10⁹/L.
* Participation in any other clinical trial (including cell or gene therapy) within 4 weeks prior to screening or within 5 half-lives of the investigational product (whichever is longer).
* Received CAR-T therapy within 6 months prior to screening.
* Treatment with B-cell-depleting agents (e.g., rituximab, or therapies targeting CD19/CD20/BAFF) within 1 month prior to screening, unless B-cell levels returned to pre-treatment or normal ranges.
* Received non-standard anti-SLE therapies (e.g., anifrolumab) within 3 months or 5 half-lives of the drug (whichever is longer) prior to screening.
* Received live/attenuated vaccination within 4 weeks prior to screening or plans to receive such during the trial.
* Active severe infection requiring antibiotic treatment within 14 days prior to screening.
* History of Grade 3-4 allergic reaction (per CTCAE v5.0) to another monoclonal antibody, or known hypersensitivity to any component of CC312 (e.g., recombinant proteins, polysorbate 80). Patients with transient (≤24 h) Grade ≤3 reactions may be included after discussion with the investigator.
* Evidence of drug abuse, substance abuse, or alcohol addiction.
* Major surgery within 4 weeks or minor surgery within 2 weeks prior to screening; wounds must be fully healed (procedures like catheter placement are excluded).
* History of cardiovascular events within 6 months prior to screening: NYHA Class III/IV heart failure, myocardial infarction, unstable angina, uncontrolled/symptomatic atrial arrhythmia, ventricular arrhythmia, or other clinically significant cardiac conditions.
* Any other severe underlying disease (e.g., active gastric ulcer, uncontrolled seizures, cerebrovascular events, GI bleeding, severe coagulation disorders), psychiatric disorder, or social circumstances that may interfere with trial conduct, compliance, or pose high risk per investigator's judgment.
* Concurrent malignancy diagnosed within \<5 years prior to screening.
* Pregnant or lactating women.
* Positive serology for HIV antibody, HBsAg, HCV antibody, or TP antibody at screening.
* Active or latent tuberculosis at screening (positive TB-IGRA test).
* Any other condition deemed ineligible by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No